Global Blood Therapeutics, Inc. (GBT) Shares Sold by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC lowered its position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 1.9% during the second quarter, Holdings Channel reports. The fund owned 9,170 shares of the company’s stock after selling 180 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Global Blood Therapeutics were worth $251,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Morgan Stanley boosted its stake in Global Blood Therapeutics by 140.0% in the first quarter. Morgan Stanley now owns 334,872 shares of the company’s stock worth $12,340,000 after buying an additional 195,323 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in Global Blood Therapeutics during the first quarter worth $694,000. Great West Life Assurance Co. Can bought a new stake in Global Blood Therapeutics during the first quarter worth $129,000. Perceptive Advisors LLC boosted its stake in Global Blood Therapeutics by 23.3% in the first quarter. Perceptive Advisors LLC now owns 3,858,978 shares of the company’s stock worth $142,203,000 after buying an additional 730,000 shares during the last quarter. Finally, Redmile Group LLC boosted its stake in Global Blood Therapeutics by 195.3% in the first quarter. Redmile Group LLC now owns 934,343 shares of the company’s stock worth $34,431,000 after buying an additional 617,943 shares during the last quarter. 72.29% of the stock is currently owned by institutional investors.

Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at 27.00 on Friday. The stock has a 50 day moving average of $28.16 and a 200-day moving average of $28.64. Global Blood Therapeutics, Inc. has a one year low of $13.35 and a one year high of $41.15. The firm’s market capitalization is $1.18 billion.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.61) by $0.06. During the same period in the prior year, the firm earned ($0.58) EPS. On average, equities analysts predict that Global Blood Therapeutics, Inc. will post ($2.48) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Global Blood Therapeutics, Inc. (GBT) Shares Sold by Gilder Gagnon Howe & Co. LLC” was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/11/global-blood-therapeutics-inc-gbt-shares-sold-by-gilder-gagnon-howe-co-llc.html.

GBT has been the topic of a number of research analyst reports. Wedbush reissued an “outperform” rating and set a $73.00 price objective on shares of Global Blood Therapeutics in a report on Tuesday, May 2nd. Morgan Stanley reissued an “overweight” rating on shares of Global Blood Therapeutics in a report on Tuesday, July 11th. Janney Montgomery Scott initiated coverage on shares of Global Blood Therapeutics in a report on Monday, May 1st. They set a “buy” rating and a $37.00 price objective on the stock. ValuEngine cut shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 3rd. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $46.00 price objective (up previously from $44.00) on shares of Global Blood Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $50.75.

In related news, Director Deval L. Patrick sold 27,053 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total transaction of $803,203.57. Following the transaction, the director now directly owns 12,053 shares in the company, valued at $357,853.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction on Friday, July 21st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the transaction, the insider now owns 143,255 shares in the company, valued at $4,297,650. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit